STXBP1 developmental and epileptic encephalopathy

What STXBP1 encephalopathy is

STXBP1 encephalopathy was first defined in 2008 in children with Ohtahara syndrome whose seizures could not be explained by structural or metabolic problems. We now know that loss-of-function variants in STXBP1 cause a wider spectrum: from Ohtahara syndrome and infantile epileptic spasms (West syndrome), through early-onset focal or generalised epilepsies, to children with severe intellectual disability and movement problems whose epilepsy is mild or absent.

Whatever the seizure picture, the developmental impact is usually significant. STXBP1 is one of the more common single-gene causes of severe DEE and is identified in roughly 1 in 10 children with infantile epileptic spasms when broad genetic testing is done.

The genetic cause (STXBP1 / Munc18-1)

STXBP1 makes a protein called syntaxin-binding protein 1 (Munc18-1), one of the central proteins at the synapse — the junction where one neuron releases neurotransmitters onto the next. Without enough Munc18-1, neurons fire and signal abnormally, which produces both the seizures and the developmental difficulties.

Almost all variants are new in the child (de novo), so the recurrence risk in a future pregnancy is very low. A wide range of variant types causes the condition: deletions, truncating variants, missense changes — most reduce the amount of working protein (haploinsufficiency), which is why "boost the working copy" strategies are so attractive.

How it presents

• Seizures starting in the first days to first months of life — tonic spasms, focal seizures or epileptic spasms are the most common first types
• Severely abnormal early EEG (burst-suppression, hypsarrhythmia or multifocal discharges)
• Severe intellectual disability that becomes apparent in the first year
• Limited or absent speech in most children; receptive understanding is variable
• Movement disorders are very common: dystonia, tremor, ataxic gait when walking is achieved, and sometimes a parkinsonian picture in older children
• Autistic features, sleep difficulties, and behaviour challenges (including anxiety, self-injury in some) become more obvious with age
• About half of children eventually walk; gross motor delay is the rule

Investigations and diagnosis

Genetic diagnosis is made by detecting a heterozygous pathogenic STXBP1 variant — through a gene panel for DEE, chromosomal microarray (for deletions), or whole-exome or whole-genome sequencing. In a child with unexplained early-onset epilepsy or epileptic spasms, broad genetic testing should be done early; it changes prognosis discussion, guides medication choice, and opens the door to research participation.

EEG and MRI are not diagnostic in themselves but help characterise the epilepsy phenotype and rule out structural causes. Many children with STXBP1 encephalopathy have a normal or only mildly abnormal MRI.

Current management

Care is multidisciplinary — paediatric neurology, developmental paediatrics, physiotherapy, occupational therapy, speech and language therapy (including AAC), and family support. Goals are to reduce seizures (especially long ones), support motor and communication development, and help families plan for the medium and long term.

• Seizure control: responses vary, but levetiracetam, vigabatrin (for spasms), valproate, and the ketogenic diet have helped in case series; sodium-channel blockers can be useful in some focal patterns
• AAC and motor therapies start early — even in children whose seizures are not yet controlled
• Active management of movement disorders (dystonia, tremor) with medicines or, in selected cases, deep brain stimulation, can transform daily life for older children
• Sleep, GI and behavioural support are often where most day-to-day improvement comes from

The research pipeline: ASO + gene therapy, with caution

Because STXBP1 encephalopathy is driven by having only half the normal amount of one protein, the rational target is straightforward: raise the level of working Munc18-1. Two complementary strategies are in active development; both remain investigational.

• ASO programmes (Stoke Therapeutics' TANGO-style approach and others) — antisense oligonucleotides given by lumbar puncture, designed to increase production of the protein from the working STXBP1 copy. Preclinical work in mice has reported reduction in seizures and improvement in survival; first-in-human studies are in late preclinical / early clinical preparation in 2025–2026.
• CAP-002 (Capsida Biotherapeutics) — an intravenously administered AAV gene therapy designed to cross the blood–brain barrier and deliver an extra STXBP1 copy. FDA granted Orphan Drug designation (Oct 2024) and IND clearance (May 2025), and the Phase 1/2a SYNRGY study began dosing. The trial was voluntarily paused in September 2025 after the first dosed patient died from unexpected cerebral oedema; Capsida is investigating the root cause before any further dosing. This is an important reminder that gene-therapy translation in young children with severe brain disease carries real, hard-to-predict risk.
• STXBP1 Foundation registry — the family-led STXBP1 Foundation runs a natural-history study and patient registry that families can join to support trial readiness and connect with the research community.

How an educational review can help

If your child has — or might have — STXBP1 encephalopathy, an educational review can summarise what is known about your child's specific variant, organise the multidisciplinary picture (seizures, movement, development), and explain the current research landscape and how it might (or might not) apply at your child's age and stage. It supports your treating team, never replaces them.